WHF IASC Roadmap on Chagas Disease
By: Luis Eduardo Echeverría, Rachel Marcus, Gabriel Novick, Sergio Sosa-Estani, Kate Ralston, Ezequiel Jose Zaidel, Colin Forsyth, Antonio Luiz P. Ribeiro, Iván Mendoza, Mariano Luis Falconi, Jorge Mitelman, Carlos A. Morillo, Ana Cristina Pereiro, María Jesús Pinazo, Roberto Salvatella, Felipe Martinez, Pablo Perel, Álvaro Sosa Liprandi, Daniel José Piñeiro and Gustavo Restrepo Molina
References
- Palafox B, Mocumbi A, Krishna Kumar K, Sulafa A. The WHF Roadmap for Reducing CV Morbidity and Mortality Through Prevention and Control of RHD: A World Heart Federation Roadmap. Global Heart, 2017; 12(1): 47–62. DOI: 10.1016/j.gheart.2016.12.001
- Grainger Gasser A, Welch C, Arora M, et al. Reducing Cardiovascular Mortality Through Tobacco Control: A World Heart Federation Roadmap. Global Heart. 2015; 10: 123–133. DOI: 10.1016/j.gheart.2015.04.007
- Adler A, Prabhakaran D, Bovet P, et al. Reducing Cardiovascular Mortality Through Prevention and Management of Raised Blood Pressure: A World Heart Federation Roadmap. Global Heart; 2015; 111–122: 10. DOI: 10.1016/j.gheart.2015.04.006
- Perel P, Avezum A, Huffman M, et al. Reducing Cardiovascular Mortality Through Tobacco Control: A World Heart Federation Roadmap. Global Heart. 2015; 10: 99–110. DOI: 10.1016/j.gheart.2015.04.003
- Murphy A, et al. The World Heart Federation Roadmap for Nonvalvular Atrial Fibrillation. Global Heart. 2017; 12(4): 273–284. DOI: 10.1016/j.gheart.2017.01.015
- Mitchell S, et al. A Roadmap on the Prevention of Cardiovascular Disease Among People Living With Diabetes. Global Heart. 2019; 14(3): 215–240. DOI: 10.1016/j.gheart.2019.07.009
- Rassi
A
Jr. , Rassi A, Marin-Neto J. Chagas Disease. The Lancet. 2010; 375(9723): 1388–1402. DOI: 10.1016/S0140-6736(10)60061-X - Chagas Disease in Latin America: An epidemiological update based on 2010 estimates. Weekly Epidemiological Record. 2015; 90(6): 33–43.
- WHO Department of Control of Neglected Tropical Diseases. Integrating neglected tropical diseases in global health and development. Fourth WHO report on neglected tropical diseases. 2017.
- Lee BY, Bacon KM, Bottazzi ME, Hotez PJ. Global economic burden of CD: A computational simulation model. Lancet Infect Dis. 2013; 13: 342–348. DOI: 10.1016/S1473-3099(13)70002-1
- Moncayo A, Silveira A. Current epidemiological trends for CD in Latin America and future challenges in epidemiology, surveillance and health policy. Mem Inst Oswaldo Cruz. 2009; 104(1): 17–30. DOI: 10.1590/S0074-02762009000900005
- Chuit R, Meiss R, Salvatella R, Altcheh J, Freilij H. Epidemiology of Chagas Disease. 2019: 351. DOI: 10.1007/978-3-030-00054-7_4
- Manne-Goehler J, Umeh CA, Montgomery SP, Wirtz VJ. Estimating the Burden of CD in the United States. PLoS Neg Trop Dis. 2016; 10(11). DOI: 10.1371/journal.pntd.0005033
- Gascon J, Bern C, Pinazo M. CD in Spain, the United States and other non-endemic countries. Acta Trop. 2010; 115(1–3): 22–27. DOI: 10.1016/j.actatropica.2009.07.019
- Lima-Costa M, Peixoto S, Ribeiro A. CD and mortality in old age as an emerging issue: 10 year follow-up of the Bambuí population-based cohort study (Brazil). Int J Cardiol. 2010; 145(2): 362–363. DOI: 10.1016/j.ijcard.2010.02.036
- Martins-Melo F, Carneiro M, Ribeiro A, Bezerra J, Werneck G. Burden of CD in Brazil, 1990–2016: findings from the Global Burden of Disease Study 2016. Int J Parasitol. 2019; 49(3–4): 301–310. DOI: 10.1016/j.ijpara.2018.11.008
- Organización Panamericana de la
Salud.
Guía para vigilancia, prevención, control y manejo clínico de la enfermedad de Chagas aguda transmitida por alimentos . Rio de Janeiro, 2009. - Silva-Dos-Santos D, Barreto-de-Albuquerque J, Guerra B, Moreira O, Berbert L, Ramos M, Mascarenhas B, Britto C, Morrot A, Serra Villa-Verde D, Garzoni L, Savino W, Cotta-de-Almeida V, de Meis J. Unraveling CD transmission through the oral route: Gateways to Trypanosoma cruzi infection and target tissues. PLoS Negl Trop Dis. 2017; 11(4). DOI: 10.1371/journal.pntd.0005507
- Altcheh
JM,
Freilij
H.
Chagas Disease: A Clinical Approach . Springer International Publishing; 2019. DOI: 10.1007/978-3-030-00054-7 - Shikanai-Yasuda MA, Carvalho NB. Oral Transmission of CD. Clinical Infectious Diseases. 2012; 54(6): 845–852. DOI: 10.1093/cid/cir956
- Capuani
L,
Bierrenbach
A, Pereira
Alencar
A,
Mendrone
A
Jr. , Ferreira J, Custer B, Ribeiro A, Cerdeira SE. Mortality among blood donors seropositive and seronegative for CD (1996–2000) in São Paulo, Brazil: A death certificate linkage study. PLoS Negl Trop Dis. 2017; 11(5). DOI: 10.1371/journal.pntd.0005542 - Stanaway J, Roth G. The burden of CD: estimates and challenges. Global Heart. 2015; 10(3): 139–144. DOI: 10.1016/j.gheart.2015.06.001
- Nunes M, Beaton A, Acquatella H, et al. Chagas cardiomyopathy: An update of current clinical knowledge and management: A scientific statement from the American Heart Association. Circulation, 138(12): e169–e209. DOI: 10.1161/CIR.0000000000000599
- Carlier
Y,
Torrico
F,
Sosa-Estani
S, et al. Congenital
CD: recommendations for diagnosis, treatment and control of newborns,
siblings and pregnant women. PLoS Negl Trop
Dis. 2011; 5(10):
e1250 . DOI: 10.1371/journal.pntd.0001250 - Prata A. Clinical and epidemiological aspects of CD. Lancet Infect Dis. 2001; 1: 92–100. DOI: 10.1016/S1473-3099(01)00065-2
- Laranja F, Dias E, Nobrega G, Miranda A. Chagas’ disease. A clinical, epidemiologic, and pathologic study. Circulation. 1956; 14: 1035–1060. DOI: 10.1161/01.CIR.14.6.1035
- Pinto
A,
Valente
S,
Valente
V,
Ferreira
A
Jr. , Coura J. Acute phase of CD in the Brazilian Amazon region: Study of 233 cases from Pará, Amapá and Maranhão observed between 1988 and 2005. Rev Soc Bras Med Trop. 2008; 41: 602. DOI: 10.1590/S0037-86822008000600011 - Echeverria L, Morillo C. American Trypanosomiasis (Chagas Disease). Infectious Disease Clinics of North America. 2019; 33(1): 119–134. DOI: 10.1016/j.idc.2018.10.015
- Lewis MD, Francisco AF, Jayawardhana S, Langston H, Taylor MC, Kelly JM. Imaging the development of chronic CD after oral transmission. Scientific Reports. 2008; 8(1). DOI: 10.1038/s41598-018-29564-7
- Almeida E, Lima J, Lages-Silva E, Guariento M, Aoki F, et al. Chagas’ disease and HIV co-infection in patients without effective antiretroviral therapy: prevalence, clinical presentation and natural history. Trans R Soc Trop Med Hyg. 2010; 104: 447–452. DOI: 10.1016/j.trstmh.2010.02.004
- Pierrotti L, Carvalho N, Amorin J, Pascual J, Kotton C, López-Vélez R. CD Recommendations for Solid-Organ Transplant Recipients and Donors. Transplantation, 2008; 102(2S): S1–S7. DOI: 10.1097/TP.0000000000002019
- Organización Panamericana de la Salud. Guía para el diagnóstico y el tratamiento de la enfermedad de Chagas. Washington, DC: OPS; 2018.
- Pinazo
M,
Espinosa
G,
Cortes-Lletget
C, et al.
Immunosuppression and CD: A management
challenge. PLoS Negl Trop Dis.
2013; 7(1):
e1965 . DOI: 10.1371/journal.pntd.0001965 - Lattes R, Lasala MB. CD in the immunosuppressed patient. Clinical Microbiology and Infection. 2014; 20(4): 300–309. DOI: 10.1111/1469-0691.12585
- Rojas L, Glisic M, Pletsch-Borba L, et al. Electrocardiographic abnormalities in CD in the general population: A systematic review and meta-analysis. PLoS Negl Trop Dis. 2018; 12(6). DOI: 10.1371/journal.pntd.0006567
- Acquatella H, Asch F, Barbosa M, et al. Recommendations for Multimodality Cardiac Imaging in Patients with CD: A Report from the American Society of Echocardiography in Collaboration With the InterAmerican Association of Echocardiography (ECOSIAC) and the Cardiovascular Imaging Department. Journal of the American Society of Echocardiography. 2018; 31(1): 3–25. DOI: 10.1016/j.echo.2017.10.019
- Presence of parasite. Am. J. Trop. Med. Hyg. 2004; 70(2): 210–220.
- Schijman AG, et al. Trypanosoma Cruzi Dna In Cardiac Lesions of Argentinean Patients with End-Stage Chronic Chagas Heart Disease. The American Journal of Tropical Medicine and Hygiene. 2004; 70(2). DOI: 10.4269/ajtmh.2004.70.210
- Shen L, Ramires F, Martinez F, Bodanese L, Echeverría L, Gómez E, et al. Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared with Other Nonischemic and Ischemic Cardiomyopathy. Circ Heart Fail. 2017; 10(11). DOI: 10.1161/CIRCHEARTFAILURE.117.004361
- Bocchi E, Bestetti R, Scanavacca M, Cunha Neto E, Issa V. Chronic Chagas Heart Disease Management: From Etiology to Cardiomyopathy Treatment. J Am Coll Cardiol. 2017; 70(12): 1510–1524. DOI: 10.1016/j.jacc.2017.08.004
- Echeverria L, Rojas L, Calvo L, et al. Profiles of cardiovascular biomarkers according to severity stages of Chagas cardiomyopathy. Int J Cardiol. 2017; 227: 577–582. DOI: 10.1016/j.ijcard.2016.10.098
- Gurevitz JM, Gaspe MS, Enriquez GF, Vassena CV, Alvarado-Otegui JA, Provecho YM, Mougabure Cueto GA, Picollo MI, Kitron U, Gürtler RE. Unexpected Failures to Control CD Vectors With Pyrethroid Spraying in Northern Argentina. Journal of Medical Entomology. 2012; 49(6): 1379–1386. DOI: 10.1603/ME11157
- Gürtler RE, Kitron U, Cecere C, Segura EL, Cohen JE. Sustainable vector control and management of CD in the Gran Chaco, Argentina. Proceedings of the National Academy of Sciences. 2007; 104(41): 16194–16199. DOI: 10.1073/pnas.0700863104
- Abad-Franch F, Diotaiuti L, Gurgel-Gonçalves R, Gürtler R. Certifying the interruption of CD transmission by native vectors: cui bono? Mem Inst Oswaldo Cruz. 2013; 108(2): 251–254. DOI: 10.1590/0074-0276108022013022
- Samuels A, Clark E, Galdos-Cardenas G, et al. Epidemiology of and impact of insecticide spraying on CD in communities in the Bolivian Chaco. PLoS Negl Trop Dis. 2013; 7(8). DOI: 10.1371/journal.pntd.0002358
- Rojas-de-Arias A. CD prevention through improved housing using an ecosystem approach to health. Cadernos de Saúde Pública, 2001; 17: S89–S97. DOI: 10.1590/S0102-311X2001000700017
- Sosa-Estani S, Cura E, Velazquez E, Yampotis C, Segura E. Etiological treatment of young women infected with Trypanosoma cruzi, and prevention of congenital transmission. Revista da Sociedade Brasileira de Medicina Tropical. 2009; 42(5): 484–487. DOI: 10.1590/S0037-86822009000500002
- Fabbro D, Danesi E, Olivera V, Codebó, M, Denner S, Heredia C, et al. Trypanocide Treatment of Women Infected with Trypanosoma cruzi and Its Effect on Preventing Congenital Chagas. PLOS Neglected Tropical Diseases. 2014; 8(11): e3312. DOI: 10.1371/journal.pntd.0003312
- Moscatelli G, Moroni S, García-Bournissen F, Ballering G, Bisio M, Freilij H, et al. Prevention of congenital Chagas through treatment of girls and women of childbearing age. Memórias do Instituto Oswaldo Cruz. 2015; 110(4): 507–509. DOI: 10.1590/0074-02760140347
- Dr. Mario Fatala Chaben, Instituto
Nacional de Parasitologia.
Pautas para la atención al paciente infectado con Trypanosoma cruzi (Enfermedad de Chagas) . Buenos Aires: Ministerio de Salud; 2015. - Dias
J,
Ramos
A
Jr. , Gontijo E, Luquetti A, Shikanai-Yasuda M, Coura J, et al. Second Brazilian Consensus on CD. Revista da Sociedade Brasileira de Medicina Tropical. 2016; 49(3): 60. DOI: 10.1590/0037-8682-0504-2016 - Verani J, Montgomery S, Schulkin J, Anderson B, Jones J. Survey of obstetrician-gynecologists in the United States about CD. Am J Trop Med Hyg. 2010; 83(4): 891–895. DOI: 10.4269/ajtmh.2010.09-0543
- Sicuri E, Muñoz J, Pinazo M, Posada E, Sanchez J, Alonso P, Gascon J. Economic evaluation of Chagas disease screening of pregnant Latin American women and of their infants in a non endemic area. Acta Trop. 2011; 118(2): 110–117. DOI: 10.1016/j.actatropica.2011.02.012
- Edwards MS, Stimpert KK, Bialek SR, Montgomery SP. Evaluation and Management of Congenital CD in the United States. Journal of the Pediatric Infectious Diseases Society. 2019; 8: 461–469. DOI: 10.1093/jpids/piz018
- Picado A, Cruz I, Redard-Jacot M, et al. The burden of congenital CD and implementation of molecular diagnostic tools in Latin America. BMJ Global Health. 2018; 3. DOI: 10.1136/bmjgh-2018-001069
- Stillwaggon E, Perez-Zetune V, Bialek S, Montgomery S. Congenital CD in the United States: Cost Savings through Maternal Screening. Am J Trop Med Hyg. 2018; 98(6): 1733–1742. DOI: 10.4269/ajtmh.17-0818
- Pan American Health Organization. EMTCT Plus, Framework for elimination of mother-to child transmission of HIV, Syphilis, Hepatitis B, and Chagas. Washington, DC: PAHO; 2017.
- Ferreira R, Cabral M, Martins R, et al. Detection and genotyping of Trypanosoma cruzi from açai products commercialized in Rio de Janeiro and Pará, Brazil. Parasit Vectors. 2018; 11(1): 233. DOI: 10.1186/s13071-018-2699-6
- Nóbrega A, Garcia M, Tatto E, Obara M, Costa E, Sobel J, Araujo W. Oral Transmission of CD by Consumption of Acai Palm Fruit, Brazil. Emerging Infectious Diseases. 2009; 15(4): 653–655. DOI: 10.3201/eid1504.081450
- Casadei D. Chagas’ disease and solid organ transplantation. Transplant Proc. 2010; 42(9): 3354–3359. DOI: 10.1016/j.transproceed.2010.09.019
- Organización Panamericana de la Salud. Suministro de sangre para transfusiones en los países de Latinoamérica y el Caribe 2012 y 2013. Washington DC: OPS; 2015.
- Reporte del grupo de trabajo
científico sobre la enfermedad de Chagas.
Programa Especial de Investigaciones y Enseñanzas sobre Enfermedades Tropicales (TDR) , Buenos Aires. 2005. - Requena-Méndez
A,
Albajar-Viñas
P,
Angheben
A,
Chiodini
P,
Gascón
J,
Muñoz
J. Health policies
to control CD transmission in European countries.
PLoS Negl Trop Dis. 2014;
8(10):
e3245 . DOI: 10.1371/journal.pntd.0003245 - Hofflin JM, Sadler RH, Araujo FG, Page WE, Remington JS. Laboratory-acquired CD. Transactions of the Royal Society of Tropical Medicine and Hygiene. 1987; 81(3): 437–440. DOI: 10.1016/0035-9203(87)90162-3
- Salvatella R. Una visión de la enfermedad de Chagas desde su propia historia. Organización Panamericana de la Salud y Fundación Mundo Sano. 2006: 19–22.
- Pereira G, Louzada-Neto F, Barbosa V, Ferreira-Silva MM, de Moraes-Souza H. Performance of six diagnostic tests to screen for CD in blood banks and prevalence of Trypanosoma cruzi infection among donors with inconclusive serology screening based on the analysis of epidemiological variables. Revista brasileira de hematologia e hemoterapia. 2012; 34(4): 292–297. DOI: 10.5581/1516-8484.20120074
- Pinazo M, Miranda B, Rodríguez-Villar C, Altclas J, Brunet Serra M, García-Otero E, de Almeida E, de la Mata García M, Gascon J, García Rodríguez M, Manito N, Moreno Camacho A, Oppenheimer F, Puente S, Riarte A, Coronas J, Salavert Lletí M, Sanz G, Torrico H, Torrús Tendero D, Ussetti P, Shikanai-Yasuda M. Recommendations for management of CD in organ and hematopoietic tissue transplantation programs in nonendemic areas. Transplant Rev. 2011; 25(3): 91–101. DOI: 10.1016/j.trre.2010.12.002
- Alonso-Padilla J, Cortés-Serra N, Pinazo M, Bottazzi M, et al. Strategies to enhance access to diagnosis and treatment for CD patients in Latin America. Expert Review of Anti-infective Therapy. 2019: 145–157. DOI: 10.1080/14787210.2019.1577731
- Cucunubá Z, Manne-Goehler J, Diaz D, Nouvellet P, Bernal O, Marchiol A, et al. How universal is coverage and access to diagnosis and treatment for CD in Colombia? A health systems analysis. Soc Sci Med. 2017; 175: 187–198. DOI: 10.1016/j.socscimed.2017.01.002
- Verani J, Seitz A, Gilman R, LaFuente C, Galdos-Cardenas G, Kawai V, et al. Geographic variation in the sensitivity of recombinant antigen-based rapid tests for chronic Trypanosoma cruzi infection. Am J Trop Med Hyg. 2009; 80(3): 410–415. DOI: 10.4269/ajtmh.2009.80.410
- Manne J, Snively C, Ramsey J, Salgado M, Barnighausen T, Reich M. Barriers to treatment access for CD in Mexico. PLoS Negl Trop Dis. 2013; 7(10): e2488. DOI: 10.1371/journal.pntd.0002488
- Manne-Goehler J, Reich M, Wirtz V. Access to Care for CD in the United States: A Health Systems Analysis. Am J Trop Med Hyg. 2015; 93(1): 108–113. DOI: 10.4269/ajtmh.14-0826
- Stimpert K, Montgomery S. Physician Awareness of CD. Emerg Infect Dis. 2010; 16(5): 871–872. DOI: 10.3201/eid1605.091440
- Pérez-Molina JA, Molina I. Chagas Disease. The Lancet. 2018; 391(10115): 82–94. DOI: 10.1016/S0140-6736(17)31612-4
- De Rissio A, Riarte A, García M, Esteva M, Quaglino M, Ruiz A. Congenital Trypanosoma cruzi infection. Efficacy of its monitoring in an urban reference health center in a non-endemic area of Argentina. Am J Trop Med Hyg. 2010; 82(5): 838–845. DOI: 10.4269/ajtmh.2010.08-0383
- Bern C, Verastegui M, Gilman R, et al. Congenital Trypanosoma cruzi transmission in Santa Cruz, Bolivia. Clin Infect Dis. 2009; 49(11): 1667–1674. DOI: 10.1086/648070
- Mora M, Sanchez Negrette O, Marco D, et al. Early diagnosis of congenital Trypanosoma cruzi infection using PCR, hemoculture, and capillary concentration, as compared with delayed serology. J Parasitol. 2005; 91(6): 1468–1473. DOI: 10.1645/GE-549R.1
- Rivero R, Bisio M, Velazquez E, et al. Rapid detection of T. Cruzi by colorimetric loop-mediated isothermal amplification (LAMP): A potential novel tool for the detection of congenital Chagas infection. Diagn Microbiol Infect Dis. 2017; 89: 26–28. DOI: 10.1016/j.diagmicrobio.2017.06.012
- Cura C, Ramírez J, Rodríguez M, Lopez-Albízu C, Irazu L, Scollo K, Sosa-Estani S. Comparative Study and Analytical Verification of PCR Methods for the Diagnosis of Congenital CD. J Mol Diagn. 2017; 19(5): 673–681. DOI: 10.1016/j.jmoldx.2017.05.010
- Besuschio S et al. Analytical sensitivity and specificity of a loop-mediated isothermal amplification (LAMP) kit prototype for detection of Trypanosoma cruzi DNA in human blood samples. PLoS Negl Trop Dis. 2017; 11(7). DOI: 10.1371/journal.pntd.0005779
- Schijman AG. Molecular diagnosis of Trypanosoma cruzi. Acta Tropica. 2018; 184: 59–66. DOI: 10.1016/j.actatropica.2018.02.019
- Riarte A, Luna C, Sabatiello R, Sinagra A, Schiavelli R, De Rissio A, Maiolo E, García MM, Jacob N, Pattin M, Lauricella M, Segura EL, Vàzquez M. Chagas’ Disease in Patients with Kidney Transplants: 7 Years of Experience, 1989–1996. Clinical Infectious Diseases. 1999; 29(3): 561–567. DOI: 10.1086/598634
- Altcheh J, Moscatelli G, Moroni S, et al. Adverse Events After the Use of Benznidazole in Infants and Children With CD. Pediatrics. 2011: 127. DOI: 10.1542/peds.2010-1172
- Pan American Health
Organization.
Guidelines for the diagnosis and treatment of Chagas disease . Washington, DC: PAHO; 2019. - Cerisola JA. Chemotherapy of Chagas’ infection in man. Scientific Publication PAHO. 1977; 347: 35–47.
- Russomando G, De Tomassone M, De Guillen I, et al. Treatment of congenital chagas’ disease diagnosed and followed up by the polymerase chain reaction. American Journal of Tropical Medicine and Hygiene. 1998; 59(3): 487–491. DOI: 10.4269/ajtmh.1998.59.487
- Schijman AG, Altcheh J, Burgos JM, et al. Aetiological treatment of congenital Chagas’ disease diagnosed and monitored by the polymerase chain reaction. Journal of Antimicrobial Chemotherapy. 2003; 52(3): 441–449. DOI: 10.1093/jac/dkg338
- Moscatelli G, Moroni S, García Bournissen F, González N, Ballering G, Schijman A, Corral R, Bisio M, Freilij H, Altcheh J. Longitudinal follow up of serological response in children treated for CD. PLoS Negl Trop Dis. 2019; 13(8). DOI: 10.1371/journal.pntd.0007668
- Alonso-Vega C, Billot C, Torrico F. Achievements and challenges upon the implementation of a program for national control of congenital Chagas in Bolivia: results 2004–2009. PLoS Negl Trop Dis. 2013; 7(7). DOI: 10.1371/journal.pntd.0002304
- Moya PR, Paolasso RD, Blanco S. Treatment of CD with nifurtimox during the first months of life. Medicina. 1985; 45(5): 553–558.
- Blanco SB, Segura EL, Cura EN, et al. Congenital transmission of Trypanosoma cruzi: An operational outline for detecting and treating infected infants in northwestern Argentina. Tropical Medicine and International Health. 2000; 5(4): 293–301. DOI: 10.1046/j.1365-3156.2000.00548.x
- Fragata-Filho A, França F, Fragata C, et al. Evaluation of parasiticide treatment with benznidazole in the electrocardiographic, clinical, and serological evolution of CD. PLoS Negl Trop Dis. 2016; 10(3). DOI: 10.1371/journal.pntd.0004508
- Morillo
C,
Marin-Neto
J,
Avezum
A,
Sosa-Estani
S,
Rassi
A
Jr. , Rosas F, et al. Randomized Trial of Benznidazole for Chronic Chagas’ Cardiomyopathy. N Engl J Med. 2015; 373(4): 1295–1306. DOI: 10.1056/NEJMoa1507574 - Sperandio da Silva G, Mediano M, Hasslocher-Moreno A, Holanda M, Silvestre de Sousa A, Sangenis L, et al. Benznidazole treatment safety: The Medecins Sans Frontieres experience in a large cohort of Bolivian patients with Chagas’ disease. J Antimicrob Chem. 2017; 72(9): 2596–2601. DOI: 10.1093/jac/dkx180
- García-Bournissen F, Moroni S, Marson M, Moscatelli G, Mastrantonio G, Bisio M, Cornou L, Ballering G, Altcheh J. Limited infant exposure to benznidazole through breast milk during maternal treatment for CD. Arch Dis Child. 2015; 100(1): 90–94. DOI: 10.1136/archdischild-2014-306358
- Moroni S, Marson M, Moscatelli G, Mastrantonio G, Bisio M, Gonzalez N, Ballering G, Altcheh J, García-Bournissen F. Negligible exposure to nifurtimox through breast milk during maternal treatment for CD. PLoS Negl Trop Dis. 2019; 13(8). DOI: 10.1371/journal.pntd.0007647
- Sguassero
Y,
Cuesta
C,
Roberts
K,
Hicks
E,
Comandé
D,
Ciapponi
A,
Sosa-Estani
S. Course of Chronic
Trypanosoma cruzi Infection after Treatment Based on Parasitological and
Serological Tests: A Systematic Review of Follow-Up Studies.
PLoS One. 2015;
10(10):
e0139363 . DOI: 10.1371/journal.pone.0139363 - Sguassero Y, Roberts K, Harvey G, Comandé D, Ciapponi A, Cuesta C, Aguiar C, Castro A, Danesi E, de Andrade A, de Lana M, Escribà J, Fabbro D, Fernandes C, Flores-Chávez M, Hasslocher-Moreno A, Jackson Y, Lacunza C, Machado-de-Assis G, Maldonado M, et al. Course of serological tests in treated subjects with chronic Trypanosoma cruzi infection: A systematic review and meta-analysis of individual participant data. Int J Infect Dis. 2018; 73: 93–101. DOI: 10.1016/j.ijid.2018.05.019
- Sosa-Estani S, Segura E. Etiological treatment in patients infected by Trypanosoma cruzi: Experiences in Argentina. Current opinion in infectious diseases. 2006; 19(6): 583–587. DOI: 10.1097/01.qco.0000247592.21295.a5
- Müller Kratz J, Garcia Bournissen F, Forsyth CJ, Sosa-Estani S. Clinical and pharmacological profile of benznidazole for treatment of CD. Expert Review of Clinical Pharmacology. 2018; 11(10): 943–957. DOI: 10.1080/17512433.2018.1509704
- Sosa Estani S, Segura E, Ruiz A, Velazquez E, Porcel B, Yampotis C. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of CD. The American Journal of Tropical Medicine and Hygiene. 1998; 59(4): 526–529. DOI: 10.4269/ajtmh.1998.59.526
- Viotti R, Vigliano C, Lococo B et al. Long-term cardiac outcomes of treating chronic CD with benznidazole versus no treatment: A nonrandomized trial. Annals of Internal Medicine. 2006; 144(10): 724–734. DOI: 10.7326/0003-4819-144-10-200605160-00006
- Fabbro D, Streiger M, Arias E, Bizai M, del Barco M, Amicone N. Trypanocide treatment among adults with chronic CD living in Santa Fe city (Argentina), over a mean follow-up of 21 years: Parasitological, serological and clinical evolution. Revista da Sociedade Brasileira de Medicina Tropical. 2007; 40(1): 1–10. DOI: 10.1590/S0037-86822007000100001
- Cardoso C, Ribeiro A, Oliveira C, Oliveira L, Ferreira A, Bierrenbach A, Silva J, Colosimo E, Ferreira J, Lee T, Busch M, Reingold A, Sabino E. Beneficial effects of benznidazole in CD: NIH SaMi-Trop cohort study. PLoS Negl Trop Dis. 2018; 12(11). DOI: 10.1371/journal.pntd.0006814
- Morillo C, Waskin H, Sosa-Estani S, et al. Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic T. Cruzi Carriers: The STOP-CHAGAS Trial. Journal of the American College of Cardiology. 2017; 69(8): 939–947. DOI: 10.1016/j.jacc.2016.12.023
- Torrico F, Gascon J, Ortiz L, et al. Treatment of adult chronic indeterminate CD with benznidazole and three E1224 dosing regimens: A proof-of-concept, randomised, placebo-controlled trial. The Lancet Infectious Diseases. 2018; 18(4): 419–430. DOI: 10.1016/S1473-3099(17)30538-8
- Molina I, Gómez I, Prat J, Salvador F, et al. Randomized Trial of Posaconazole and Benznidazole for Chronic Chagas’ Disease. New England Journal of Medicine. 2014; 370(20): 1899–1908. DOI: 10.1056/NEJMoa1313122
- DNDi. Chagas BENDITA Study Briefing Document. 2019.
- Forsyth C, Hernandez S, Flores C, Roman M, Nieto J, Marquez G, et al. “It’s Like a Phantom Disease”: Patient Perspectives on Access to Treatment for CD in the United States. The American Journal of Tropical Medicine and Hygiene. 2018; 98(3): 735–741. DOI: 10.4269/ajtmh.17-0691
- Andrade J, et al. Latin American guidelines for the diagnosis and treatment of Chagas’ heart disease: Executive summary. Bras Cardiol. 2011; 96(43).
- Filigheddu M, Górgolas M, Ramos J. Orally-transmitted CD. Med Clin (Barc). 2017; 148(3): 125–131. DOI: 10.1016/j.medcli.2016.10.038
- Botoni FA, et al. A Randomized Trial of Carvedilol after Renin-Angiotensin System Inhibition in Chronic Chagas Cardiomyopathy. American Heart Journal. 2007; 153(4). DOI: 10.1016/j.ahj.2006.12.017
- Novartis Pharmaceuticals. Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With Chagas Cardiomiophaty (PARACHUTE-HF). ClinicalTrials.gov. 2019.
- Fernandes
F.
Colchicine for Patients With Chagas’ Disease (B1 Stage) (COACH) . University of Sao Paulo General Hospital; 2018. - Cardoso R, Macedo F, Garcia D, Benjo A, Aguilar D, et al. Chagas cardiomyopathy is associated with higher incidence of stroke: A meta-analysis of observational studies. J Card Fail. 2014; 20(12): 931–938. DOI: 10.1016/j.cardfail.2014.09.003
- de Sousa A, Xavier S, de Freitas G, Hasslocher-Moreno A. Prevention strategies of cardioembolic ischemic stroke in Chagas’ disease. Arq Bras Cardiol. 2008; 91(5): 306–310. DOI: 10.1590/S0066-782X2008001700004
- Villar
J,
Rodriguez
D. A Trial Testing
Amiodarone in Chagas Cardiomyopathy (ATTACH). Identification
No. NCT03193749, 2017. [Online]. Available:
https://clinicaltrials.gov/ct2/show/NCT03193749 . - Martinelli
M. Amiodarone
Against ICD Therapy in Chagas Cardiomyopathy for Primary Prevention of Death
(CHAGASICS). Identification No. NCT01722942.
2014. [Online]. Available:
https://clinicaltrials.gov/ct2/show/NCT01722942 . - Kransdorf E, Zakowski P, Kobashigawa J. CD in solid organ and heart transplantation. Curr Opin Infect Dis. 2014; 27(5): 418–424. DOI: 10.1097/QCO.0000000000000088
- Clark
E,
Sherbuk
J,
Okamoto
E,
Jois
M,
Galdos-Cardenas
G, et al.
Hyperendemic CD and the Unmet Need for Pacemakers in the
Bolivian Chaco. PLOS Neglected Tropical
Diseases. 2014; 8(6):
e2801 . DOI: 10.1371/journal.pntd.0002801 - Jackson Y, Alirol E, Getaz L, Wolff H, Combescure C, Chappuis F. Tolerance and safety of nifurtimox in patients with chronic CD. Clin Infect Dis. 2010; 51(10): e69–e75. DOI: 10.1086/656917
- Hidron
A,
Gilman
R,
Justiniano
J,
Blackstock
A,
LaFuente
C, et al. Chagas
Cardiomyopathy in the Context of the Chronic Disease
Transition. PLOS Neglected Tropical
Diseases. 2010; 4(5):
e688 . DOI: 10.1371/journal.pntd.0000688 - de Almeida AE, et al. Co-infection Trypanosoma cruzi/HIV: Systematic review (1980–2010) Rev Soc Bras Med Trop. 2011; 44(6): 762–770. DOI: 10.1590/S0037-86822011000600021
- Ribeiro
I,
Sevcsik
A,
Alves
F,
Diap
G,
Don
R,
Harhay
M,
Chang
S,
Pecoul
B. New, improved
treatments for CD: From the R&D pipeline to the
patients. PLoS Negl Trop Dis.
2009; 3(7):
e484 . DOI: 10.1371/journal.pntd.0000484 - Kong
A,
Warren
M,
Edwards
D,
Karrar
K,
Iyer
JK.
Are pharmaceutical companies making progress when it comes to global health? Access to Medicine Foundation. May 2019. - Pratt B, Loff B. Linking Research to Global Health Equity: The Contribution of Product Development Partnerships to Access to Medicines and Research Capacity Building. American Journal of Public Health. 2013; 103(11): 1968–978. DOI: 10.2105/AJPH.2013.301341
- Sánchez-Valdéz F, Padilla A. In Situ Detection of Dormant Trypanosoma cruzi Amastigotes Using Bioluminescent-Fluorescent Reporters. Methods Mol Biol. 2019; 1955: 179–186. DOI: 10.1007/978-1-4939-9148-8_13
- Beaumier C, Gillespie P, Strych U, et al. Status of vaccine research and development of vaccines for CD. Vaccine. 2016; 34: 2996–3000. DOI: 10.1016/j.vaccine.2016.03.074
- Jones K, Versteeg L, Damania A, et al. Vaccine-linked chemotherapy improves benznidazole efficacy for acute CD. infect Immun. 2018; 86. DOI: 10.1128/IAI.00876-17
- Pinazo M-J, Pinto J, Ortiz L, et al. A strategy for scaling up access to comprehensive care in adults with Chagas disease in endemic countries: The Bolivian Chagas Platform. PLOS Neglected Tropical Diseases. 2017. DOI: 10.1371/journal.pntd.0005770
- Batista
C,
Forsyth
C,
Herazo
R,
Certo
M,
Marchiol
A. A four-step
process for building sustainable access to diagnosis and treatment of Chagas
disease. Rev Panam Salud Publica.
2019; 43:
e74 . DOI: 10.26633/RPSP.2019.74 - Pennington
P,
Juárez
J,
Arrivillaga
M, De
Urioste-Stone
S,
Doktor
K,
Bryan
J,
Cordón-Rosales
C. Towards Chagas
disease elimination: Neonatal screening for congenital transmission in rural
communities. PLoS Negl Trop Dis.
2017; 11(9):
e0005783 . DOI: 10.1371/journal.pntd.0005783 - Engam D, Engam B, Engam K. Chagas Heart Disease Pathogenesis: One Mechanism or Many? Current Molecular Medicine. 2008; 8(6): 510–518. DOI: 10.2174/156652408785748004
- Tanowitz HB, et al. Developments in the Management of Chagas Cardiomyopathy. Expert Review of Cardiovascular Therapy. 2015; 13(12): 1393–1409. DOI: 10.1586/14779072.2015.1103648
- Chevillard C, et al. Disease Tolerance and Pathogen Resistance Genes May Underlie Trypanosoma Cruzi Persistence and Differential Progression to Chagas Disease Cardiomyopathy. Frontiers. 2018. DOI: 10.3389/fimmu.2018.02791
- Pinazo M, Thomas M, Bua J, Perrone A, Schijman A, Viotti R, Ramsey J, Ribeiro I, Sosa-Estani S, Lopez M, Gascon J. Biological markers for evaluating therapeutic efficacy in Chagas disease: A systematic review. Expert Rev Anti Infect Ther. 2014; 12(4): 479–496. DOI: 10.1586/14787210.2014.899150
- Albareda M, Laucella S. Modulation of Trypanosoma Cruzi-Specific T-Cell Responses after Chemotherapy for Chronic Chagas Disease. Memórias Do Instituto Oswaldo Cruz. 2015; 110(3): 414–421. DOI: 10.1590/0074-02760140386
- Albareda M, et al. Distinct Treatment Outcomes of Antiparasitic Therapy in Trypanosoma Cruzi-Infected Children Is Associated With Early Changes in Cytokines, Chemokines, and T-Cell Phenotypes. Frontiers in Immunology. 2018; 9. DOI: 10.3389/fimmu.2018.01958
- Sánchez-Valdéz F, Padilla A, Wang W, Orr D, Tarleton R. Spontaneous dormancy protects Trypanosoma cruzi during extended drug exposure. Elife. 2018; 7. DOI: 10.7554/eLife.34039
- Mendoza N, de la Torre Avilé L. Chagas Workshop. Pasa la Voz project. 2016.
- Sanmartino M, Saavedra A, Prat J, Barba M, Albajar-Viñas P. Que no tengan miedo de nosotros:el Chagas según los propios protagonistas. Interface – Comunicação, Saúde, Educação. 2015; 19: 1063–1075. DOI: 10.1590/1807-57622014.1170
- Forsyth C. I Cannot Be Worried: Living with CD in Tropical Bolivia. PLoS Negl Trop Dis. 2017; 11(1). DOI: 10.1371/journal.pntd.0005251
- Sanchez D, Traina M, Hernandez S, Smer A, Khamag H, Meymandi S. CD awareness among Latin American immigrants living in Los Angeles, California. The American Journal of Tropical Medicine and Hygiene. 2014; 91(5): 915–919. DOI: 10.4269/ajtmh.14-0305
- Ozaki Y, Guariento M, de Almeida E. Quality of life and depressive symptoms in CD patients. Qual Life Res. 2011; 20(1): 133–138. DOI: 10.1007/s11136-010-9726-1
- Ventura-Garcia
L,
Roura
M,
Pell
C,
Posada
E,
Gascón
J,
Aldasoro
E, et al.
Socio-Cultural Aspects of CD: A Systematic Review of
Qualitative Research. PLOS Neglected Tropical
Diseases. 2013; 7(9):
e2410 . DOI: 10.1371/journal.pntd.0002410 - Oliveira
W,
Jr . All-around care for patients with CD: a challenge for the XXI century. Memorias do Instituto Oswaldo Cruz. 2009; 104(1): 181–186. DOI: 10.1590/S0074-02762009000900024 - 2nd Brazilian Consensus on CD. In Epidemiol. Brasilia; 2015.
- Manual de procedimiento para la atención de pacientes con enfermedad de Chagas. Plan Nacional de Control y Prevención de Enfermedad de Chagas Ministerio de Salud de Chile; 2017.
- Ministerio de Salud de la
Nación.
Chagas: Atención del paciente infectado con Trypanosoma cruzi . BAJA: Dirección de Epidemiología, Buenos Aires; 2018. - Guia para el Diagnóstico, Atención y Manejo Clínico de la Enfermedad de Chagas en Venezuela. República Bolivariana de Venezuela Ministerio del Poder Popular para la Salud; 2014.
- Ministério da Saúde,
Secretaria de Ciência, Tecnologia e Insumos Estratégicos.
Protocolo Clínico e Diretrizes Terapêuticas em Doença de Chagas . Brazilian Ministry of Health, 2018. - Pérez- Molina J, Rodríguez-Guardado S, Soriano A, Pinazo M, et al. Guidelines on the treatment of chroniccoinfection by Trypanosoma cruzi and HIV outside endemic areas. HIV Clin Trials. 2011; 12(6): 287–298. DOI: 10.1310/hct1206-287
- Pinazo M, Cañas E, Elizalde J, Garcia M, et al. Diagnosis, management and treatment of chronic Chagas’ gastrointestinal disease in areas where Trypanosoma cruzi infection is not endemic. Gastroenterol Hepatol. 2010; 33(3): 191–200. DOI: 10.1016/j.gastrohep.2009.07.009
- Gascón J, Albajar P, Cañas E, Flores M, et al. Diagnosis, management and treatment of chronic Chagas’ heart disease in areas where Trypanosoma cruzi infection is not endemic. Rev EspCardiol. 2007; 60(3): 285–293. DOI: 10.1016/S1885-5857(07)60153-4
- Abbott, AstraZeneca, Bayer, Becton
Dickinson, Bill & Melinda Gates Foundation, et al.
London Declaration on Neglected Tropical Diseases . London; 2012. - World Health Organization.
Accelerating work to overcome the global impact of Neglected Tropical Diseases . A Roadmap for Elimination. WHO; 2012. - Mathers
C,
Ezzati
M,
Lopez
A. Measuring the
burden of neglected tropical diseases: The global burden of disease
framework. PLoS Negl Trop Dis.
2007; 1:
e114 . DOI: 10.1371/journal.pntd.0000114 - TDR, the Special Programme for Research and Training in Tropical Diseases. MosquitiaMed: Shortening Distances Through Telemedicine. Social Innovation in Health Initiative; 2019. [Online].
- Marcolino M, Palhares D, Ferreira L, Ribeiro A. Electrocardiogram and CD: A large population database of primary care patients. Global Heart. 2015; 10(3): 167–172. DOI: 10.1016/j.gheart.2015.07.001
- Nascimento BR, Beaton AZ, Nunes MCP, et al. PROVAR+ (Programa de RastreamentO da VAlvopatia Reumática and Other Cardiovascular Diseases) investigators. Integration of echocardiographic screening by non-physicians with remote reading in primary care. Heart. 2019; 105(4): 283–90. DOI: 10.1136/heartjnl-2018-313593
- Cormick G, Ciganda A, Cafferata M, Ripple M, et al. Text message interventions for follow up of infants born to mothers positive for CD in Tucumán, Argentina: A feasibility study. BMC Res Notes. 2015; 8. DOI: 10.1186/s13104-015-1498-9
- Jiang F, Jiang Y, Zhi H, Dong Y, Li H, Ma S, et al. Artificial intelligence in healthcare: past, present and future. Stroke and Vascular N eurology. 2017; 2(4): 230–243. DOI: 10.1136/svn-2017-000101
DOI: https://doi.org/10.5334/gh.484 | Journal eISSN: 2211-8179
Language: English
Submitted on: Dec 27, 2019
Accepted on: Jan 17, 2020
Published on: Mar 30, 2020
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
© 2020 Luis Eduardo Echeverría, Rachel Marcus, Gabriel Novick, Sergio Sosa-Estani, Kate Ralston, Ezequiel Jose Zaidel, Colin Forsyth, Antonio Luiz P. Ribeiro, Iván Mendoza, Mariano Luis Falconi, Jorge Mitelman, Carlos A. Morillo, Ana Cristina Pereiro, María Jesús Pinazo, Roberto Salvatella, Felipe Martinez, Pablo Perel, Álvaro Sosa Liprandi, Daniel José Piñeiro, Gustavo Restrepo Molina, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.